Acute exacerbation of idiopathic pulmonary fibrosis

Chest

Volumn 132, Issue 5, 2007, Pages 1652-1658

  Hyzy, Robert ^a,b   Huang, Steven ^a   Myers, Jeffrey ^a   Flaherty, Kevin ^a   Martinez, Fernando ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chest CT scan; Interstitial lung disease; Lung biopsy; Pathology lung; Pulmonary fibrosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA1B INTERFERON; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PIRFENIDONE; PLACEBO; PREDNISOLONE; STEROID;

ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSPNEA; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; LUNG TUBERCULOSIS; MONOTHERAPY; OXYGEN THERAPY; PRIORITY JOURNAL; RESPIRATORY FAILURE; VIRUS ENCEPHALITIS;

EID: 36348946221     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0299     Document Type: Article

References (50)

1. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203
2. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161:1172-1178
3. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450-454
4. Panos RJ, Mortenson RL, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396-404
5. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277-304
6. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-967
7. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993; 103:1808-1812
8. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22:821-826
9. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27:143-150
10. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128:3310-3315
11. Akira M. Computed tomography and pathologic findings in fulminant forms of idiopathic interstitial pneumonia. J Thorac Imaging 1999; 14:76-84
12. Akira M, Hamada H, Sakatani M, et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168:79-83
13. Johkoh T, Muller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999; 211:555-560
14. Rice AJ, Wells AU, Bouros D, et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias: an autopsy study. Am J Clin Pathol 2003; 119:709-714
15. Saydain G, Islam A, Afessa B, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002; 166:839-842
16. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133
17. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047
18. Dallari RM, Foglia M, Paci M, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2004; 23:792
19. Vourlekis JS, Brown KK, Cool CD, et al. Acute interstitial pneumonitis: case series and review of the literature. Medicine (Baltimore) 2000; 79:369-378
20. Quefatieh A, Stone CH, DiGiovine B, et al. Low hospital mortality in patients with acute interstitial pneumonia. Chest 2003; 124:554-559
21. Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141:727-733
22. Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995; 50:1234-1239
23. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159:1336-1341
24. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41:2633-2640
25. Kuwano K, Nomoto Y, Kunitake R, et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J 1997; 10:1445-1449
26. Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992; 146:266-268
27. Mora AL, Torres-Gonzalez E, Rojas M, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol 2006; 35:466-473
28. Honrore I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003; 167:953-967
29. Selman M. A dark side of interferon-g in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 167:945-947
30. Hiwatari N, Shimura S, Takishima T, et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994; 174:379-386
31. Suga T, Sugiyama Y, Ohno S, et al. Two cases of IIP which developed acute exacerbation after bronchoalveolar lavage. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32:174-178
32. Tasaka S, Kanazawa M, Komune Y, et al. Acute exacerbation of subacute interstitial pneumonia after thoracoscopic lung biopsy. Nihon Kokyuki Gakkai Zasshi 1998; 36:182-186
33. Kondoh Y, Taniguchi H, Kitaichi M, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006; 100:1753-1759
34. Yuksel M, Ozyurtkan MO, Bostanci K, et al. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg 2006; 82:336-338
35. Enomoto T, Kawamoto M, Kunugi S, et al. Clinicopathological analysis of patients with idiopathic pulmonary fibrosis which became acutely exacerbated after video-assisted thoracoscopic surgical lung biopsy. Nihon Kokyuki Gakkai Zasshi 2002; 40:806-811
36. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003; 125:1321-1327
37. Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection. Nippon Geka Gakkai Zasshi 2004; 105:757-762
38. Yazdy AM, Tomashefski JF Jr, Yagan R, et al. Regional alveolar damage (RAD), a localized counterpart of diffuse alveolar damage. Am J Clin Pathol 1989; 92:10-15
39. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998; 95:6930-6935
40. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187:787-794
41. Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003; 124:1206-1214
42. Okamoto T, Ichiyasu H, Ichikado K, et al. Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 2006; 44:359-367
43. Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003; 342:565-570
44. Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005; 44:1144-1150
45. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475-1482
46. Steinberg KP, Hudson LD, Goodman RB, et al. The efficacy and safety of corticosteroids as rescue therapy for persistent acute respiratory distress syndrome: the late steroid rescue study. N Engl J Med 2006; 354:1671-1684
47. Meduri GU, Golden E, Friere AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954-963
48. Fahy RJ, Lichtenberger F, McKeegan CB et al. The acute respiratory distress syndrome: a role for transforming growth factor-β1. Am J Respir Crit Care Med 2003; 28:499-503
49. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11:117-122
50. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007; 175:480-489